Cover Image
市場調查報告書

日本的學名藥市場展望

Japan Generics Drug Market Outlook 2020

出版商 KuicK Research 商品編碼 356382
出版日期 內容資訊 英文 66 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
日本的學名藥市場展望 Japan Generics Drug Market Outlook 2020
出版日期: 2016年04月19日 內容資訊: 英文 66 Pages
簡介

本報告提供日本的學名藥市場相關調查,市場概要,市場魅力度,日本的醫療制度,美國和日本的學名藥比較,市場分析,及展望等系統性資訊。

第1章 日本的學名藥市場簡介

  • 日本的學名藥的成長理由
  • 日本的學名藥相關的主要誤解

第2章 日本的學名藥的魅力

  • 日本的醫藥品市場概要
  • 日本的學名藥市場特徵
  • 日本的學名藥企業
  • 日本的學名藥的進口
  • 學名藥相關經濟性觀點

第3章 日本的學名藥狀況

  • 日本的學名藥價格狀況
  • 日本的醫藥品專利的各分類
  • 日本的學名藥的推銷

第4章 日本的超級學名藥

  • 超級學名藥的簡介
  • 超級學名藥的優點
  • 超級學名藥的缺點

第5章 日本的學名藥、首發醫藥品的各參數

  • 日本的專利保護
  • 日本的醫療費的影響
  • 對於學名藥日本的藥理學性參數
  • 法規必要條件的差異
  • 日本市場上首發醫藥品、學名藥的有效利用

第6章 日本的學名藥的醫藥品有效成分 (API)

  • 醫藥品有效成分 (API) 的登記
  • 日本的外國企業的法規
  • 非專利API的製造能力

第7章 日本的健康及非專利醫藥品的使用

  • 日本的癌症的發病率
  • 日本的糖尿病發病率的增加
  • 日本的心血管疾病發病率的增加
  • 日本的心血管疾病的發病率
  • 日本的污染原因的疾病

第8章 日本的醫療制度及學名藥

  • 萬能的醫療保險
  • 物價上升的管理
  • 學名藥的品管
  • 學名藥市場進入
  • 日本的學名藥的專利相關問題
  • 抑制日本的學名藥的普及的要素

第9章 美國、日本的學名藥比較

  • 學名藥的法律規範
  • 學名藥的市場滲透率
  • 學名藥的價格
  • 學名藥的認識

第10章 日本的學名藥市場分析

第11章 日本的學名藥市場偏好的要素

  • 人口高齡化
  • 學名藥法規
  • 高科技能力
  • 疾病發病率的上升

第12章 日本的學名藥商業化的課題

  • 日本的法規環境
  • 對於學名藥的態度
  • 學名藥的接受度低
  • 不相容的專利法

第13章 日本的學名藥市場未來預測

第14章 競爭環境

  • Actavis
  • Eisai
  • 富士藥品
  • GlaxoSmithKline
  • Hospira
  • Meiji Seika Pharma
  • Nichi-Iko Pharmaceutical
  • Nipro Pharma
  • Pfizer
  • 澤井製藥
  • 武田藥品工業
  • 東和藥品

圖表

目錄

Japan is a small island nation located in East Asia and it is known for its economic prosperity. It sports one of the largest pharmaceutical markets like US and Europe due to which immense commercialization opportunities are present. Unique demographic structure and presence of advanced technology is the main reason for the growth of Japanese pharmaceutical industry. They have one of the most advanced research and development facilities across the world contributing significantly to the development of healthcare infrastructure. Japan has opened its pharmaceutical market for foreign trade leading to higher input of drugs. Their population is going in downward spiral where number of young people are lesser then geriatric population. In this way, they have high demand for therapeutic products due which their pharmaceutical market is increasing.

Observation shows that Japanese pharmaceuticals market is heavily inclined towards consumption of branded drugs. Due to presence of higher technological capabilities they were able to commercialize innovative drugs. Significant investments were made in research and development segment due to which new products are being made. It promoted the utilization of branded drugs in Japanese market. Presence of universal healthcare system also allowed the patients to include generic drugs in their therapeutic regime. They to invest small out of pocket money while buying branded drugs as rest of the part is covered by the universal healthcare system. Branded drugs market got boost due to regulator's policies but these drugs are quite costly. As a result, stagnant economy is not able to sustain burgeoning financial pressure on healthcare system.

Japanese generic drugs market is largely unchurned due to which it offers significant commercialization opportunities. Both domestic and foreign pharmaceutical companies are expected to take advantage of this scenario. Japanese regulators have developed amenable rules due to which foreign pharmaceutical companies can venture in generic drugs segment. This will increase the competition and further decrease the prices of generic drugs in Japanese market. Moreover, it will build a strong supply chain due to which dearth of generic drugs will not occur in future. Regulators will also be able to increase their consumption by promoting more numbers of patients opting for the generic drugs. In this way, they will be able to observe decrease in investments in healthcare system. To achieve higher cost savings, more work has yet to be done in coming years.

Prices of both generic and branded drugs are checked by Japanese regulators after every two years. This allows the patients to spend less money for treatment of their diseases in long-term scenario. But it could be observed that patients are not willing to switch to the generic drugs despite lesser cost. Main reason behind this fact is that cost difference between these drugs is not significant. Higher buying power of patients allow them to include costly branded drugs in their daily therapeutic regime. This scenario shows that Japanese regulators have to further decrease the prices of generic drugs in order to offer higher cost arbitrage. They also have to increase the uptake of generic drugs in order to decrease the prevalence of branded drugs as major component of healthcare system. Some of the measures have been implemented but their results are yet to be observed in coming years.

Japanese pharmaceuticals market is quite mature and still has opportunities for growth as they have lesser market shares of generic drugs. This allows significant potential to generic firms to enter in Japanese pharmaceuticals market. Presence of amenable regulation and significant efforts made to decrease healthcare spending is expected to take place in coming years. Large geriatric population plays an important role of consumers in Japanese pharmaceutical industry. They require long-term usage of drugs and switching them from branded to generic drugs will boost the market. It also offers significant commercialization opportunities as compared to other countries where generic drugs occupy major market shares. Japanese generic drugs market is expected to grow several folds in coming years, in this way, its future looks optimistic.

“Japan Generics Drug Market Outlook 2020” Report Highlights:

  • Introduction to Japanese Generic Drug Market
  • Attractiveness of Japanese Generic Market
  • Super Generics in Japan
  • Japan Healthcare System & Generic Drugs
  • Different Parameters for Generic & Branded Drugs
  • Comparison of Generic Drugs in US & Japan
  • Japan Generics Drug Market Analysis
  • Japan Generics Drug Market Future Prospects

Table of Contents

1. Introduction to Japan Generic Drug Market

  • 1.1 Reasons for Growth of Japan Generic Market
  • 1.2 Some Misconceptions Related to Generic Drugs in Japan

2. Attractiveness of Japan Generic Market

  • 2.1 Overview of Japan Pharmaceutical Market
  • 2.2 Features of Japan Generic Drugs Market
  • 2.3 Generic Drug Firms in Japan
  • 2.4 Generic Drugs Import in Japan
  • 2.5 Economic Views about Generic Drugs

3. Scenario of Generic Drugs in Japan

  • 3.1 Scenario for Generic Drug Discount Price in Japan
  • 3.2 Different Categories of Pharmaceutical Patent in Japan
  • 3.3 Promotion of Generic Drugs in Japan

4. Super Generics in Japan

  • 4.1 Introduction to Super Generics
  • 4.2 Advantages of Super Generics
  • 4.3 Disadvantages of Super Generics

5. Different Parameters for Generic & Branded Drugs in Japan

  • 5.1 Patent Protection in Japan
  • 5.2 Effect on Japan Healthcare Spending
  • 5.3 Japan Pharmacological Parameters for Generic Drugs
  • 5.4 Difference in Regulatory Requirements
  • 5.5 Utilization of Branded & Generic Drugs in Japan Market

6. Generic Active Pharmaceutical Ingredients in Japan

  • 6.1 Generic Active Pharmaceutical Ingredient Registration
  • 6.2 Regulation for Foreign Companies in Japan
  • 6.3 Manufacturing Capabilities for Generic API 7. Health in Japan & Utilization of Generic Drugs
  • 7.1 Cancer Incidences in Japan
  • 7.2 Increasing Diabetes Incidences in Japan
  • 7.3 Increasing Cerebrovascular Incidences in Japan
  • 7.4 Cardiovascular Diseases Incidences in Japan
  • 7.5 Disease Caused by Pollution in Japan

8. Healthcare System & Generic Drugs in Japan

  • 8.1 Universal Healthcare Coverage
  • 8.2 Price Rise Control
  • 8.3 Quality Control of Generic Drugs
  • 8.4 Access to Generic Market
  • 8.5 Patents Related Issues to Generic Drugs in Japan
  • 8.6 Factors Restricting Uptake of Generic Drugs in Japan

9. Comparison of Generic Drugs in US & Japan

  • 9.1 Regulatory Framework for Generic Drugs
  • 9.2 Market Penetration of Generic Drugs
  • 9.3 Prices of Generic Drugs
  • 9.4 Perception towards Generic Drugs

10. Japan Generic Drugs Market Analysis

11. Japan Generic Market Favorable Factors

  • 11.1 Ageing Population
  • 11.2 Generic Drugs Regulations
  • 11.3 High Technological Capabilities
  • 11.4 Increasing Disease Incidences

12. Japan Generics Market Commercialization Challenges

  • 12.1 Japan Regulatory Environment
  • 12.2 Attitude towards Generic Drugs
  • 12.3 Lower uptake of Generic Drugs
  • 12.4 Conflicting Patent Laws

13. Japan Generic Drugs Market Future Prospects

14. Competitive Landscape

  • 14.1 Actavis
  • 14.2 Eisai
  • 14.3 Fuji Pharma
  • 14.4 GlaxoSmithKline
  • 14.5 Hospira
  • 14.6 Meiji Seika Pharma
  • 14.7 Nichi-Iko Pharmaceutical
  • 14.8 Nipro Pharma
  • 14.9 Pfizer
  • 14.10 Sawai Pharmaceuticals
  • 14.11 Takeda Pharmaceutical
  • 14.12 Towa Pharmaceutical

List of Figures

  • Figure 1-1: Reasons for Growth of Japan Generic Market
  • Figure 1-2: Some Steps taken by Japan Regulators to Decrease Drug Prices
  • Figure 1-3: Some Misconceptions Related to Generic Drugs in Japan
  • Figure 2-1: Some Considerations while Approaching Japan Generic Market
  • Figure 3-1: Discount Determination of Generic Drugs in Japan
  • Figure 3-2: Type of Drug Price Survey in Japan
  • Figure 4-1: Advantages of Super Generics
  • Figure 4-2: Disadvantages of Super Generics
  • Figure 5-1: Economic Benefits of opting Generic Drugs
  • Figure 5-2: Regulatory Requirement for Generic Drugs in Japan
  • Figure 5-3: Utilization of Branded and Generic Drugs in Japan Market
  • Figure 6-1: Requirements for Registration of API
  • Figure 6-2: Regulation for Foreign Companies in Japan
  • Figure 6-3: Japan - Manufacturing Capabilities for Generic API
  • Figure 7-1: Aim of Basic Plan to Promote Cancer Control Programs
  • Figure 7-2: Estimated Numbers of Cancer Cases in Japan, 2015
  • Figure 8-1: Position of Generics in Japan Healthcare System
  • Figure 8-2: Patents Related Issues to Generic Drugs in Japan
  • Figure 10-1: Japan - Generics Drug Market (US$ & Yen), 2014-2016
  • Figure 10-2: Japan - Generics Drug Share in Pharmaceutical Market (%), 2014
  • Figure 11-1: Japan - Generic Drugs Market Drivers
  • Figure 12-1: Japan - Generics Market Commercialization Challenges
  • Figure 13-1: Japan - Generics Drug Market (US$ & Yen), 2017-2020
  • Figure 13-2: Japan - Generics Drug Share of Prescription Drug (%), 2018
  • Figure 13-3: Japan - Generics Drug Share of Prescription Drug (%), 2020
  • Figure 13-4: Japan - Generics Drug Share in Pharmaceutical Market (%), 2020

List of Tables

  • Table 1-1: Some Important Features of Japan
  • Table 3-1: Listing Period for Various Drugs in Japan
  • Table 5-1: Difference between Branded and Generic Drugs in Japan
  • Table 5-2: Regulatory Requirements for Different Drugs in Japan
  • Table 7-1: Estimated Numbers of Different Cancer Affecting Japan Population, 2015
  • Table 7-2: Estimated Numbers of Males Affected by Different Type of Cancer in Japan, 2015
  • Table 7-3: Estimated Numbers of Females Affected by Different Type of Cancer in Japan, 2015
  • Table 7-4: Issues related with Cerebrovascular Diseases
  • Table 7-5: Some Important Diseases caused by Pollutants in Japan
  • Table 9-1: Difference in Regulatory Framework between Japan & US
Back to Top